Vincenzo Serretta

3.0k total citations
104 papers, 1.2k citations indexed

About

Vincenzo Serretta is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Urology. According to data from OpenAlex, Vincenzo Serretta has authored 104 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Surgery, 36 papers in Pulmonary and Respiratory Medicine and 34 papers in Urology. Recurrent topics in Vincenzo Serretta's work include Bladder and Urothelial Cancer Treatments (55 papers), Urinary and Genital Oncology Studies (42 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Vincenzo Serretta is often cited by papers focused on Bladder and Urothelial Cancer Treatments (55 papers), Urinary and Genital Oncology Studies (42 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Vincenzo Serretta collaborates with scholars based in Italy, Argentina and Japan. Vincenzo Serretta's co-authors include M. Pavone‐Macaluso, Carlo Pavone, Giuseppe Morgia, Giorgio Pomara, D. Melloni, Elisa Espósito, Domenico Pirritano, Mario Motta, Maria Rosaria Valerio and Vittorio Gebbia and has published in prestigious journals such as The Journal of Urology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Vincenzo Serretta

98 papers receiving 1.1k citations

Peers

Countries citing papers authored by Vincenzo Serretta

Since Specialization

Citations

This map shows the geographic impact of Vincenzo Serretta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincenzo Serretta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincenzo Serretta more than expected).

Fields of papers citing papers by Vincenzo Serretta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincenzo Serretta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincenzo Serretta. The network helps show where Vincenzo Serretta may publish in the future.

Co-authorship network of co-authors of Vincenzo Serretta

This figure shows the co-authorship network connecting the top 25 collaborators of Vincenzo Serretta. A scholar is included among the top collaborators of Vincenzo Serretta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincenzo Serretta. Vincenzo Serretta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer 2022 ·Anticancer Research ·Maria Rosaria Valerio, Vincenzo Serretta, (unknown), (unknown), Vincenzo Altieri, Sergio Baldari, (unknown), (unknown), Massimiliano Spada, (unknown), Marco Messina, Carlo Messina, Giorgia Leone, (unknown), (unknown), (unknown), Nicolò Borsellino, Dario Piazza, Vittorio Gebbia	1
2	Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer 2021 ·Therapeutic Advances in Urology ·Fabrizio Di Maida, (unknown), R. Tellini, Andrea Mari, (unknown), Luca Lambertini, Antonio Andrea Grosso, Marco Carini, Andrea Minervini, Vincenzo Serretta	4
3	Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes 2021 ·Journal of Cancer Research and Clinical Oncology ·Giuseppe Ferrera, Salvatore D’Alessandro, Francesco Cuccia, Vincenzo Serretta, Giovanna Di Trapani, Gianfranco Savoca, Gianluca Mortellaro, Antonio Lo Casto	5
4	Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study 2020 ·The Journal of Sexual Medicine ·Carlo Pavone, Alberto Abrate, (unknown), (unknown), Vincenzo Serretta, Alchiede Simonato, (unknown)	8
5	Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World 2020 ·Anticancer Research ·Vittorio Gebbia, (unknown), (unknown), (unknown), Nicolò Borsellino, Dario Piazza, Vincenzo Serretta, Stefano Pergolizzi, Antonio Pontoriero, Alberto Firenze, Maria Rosaria Valerio	12
6	Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis 2019 ·La radiologia medica ·Francesco Cuccia, Gianluca Mortellaro, Giovanna Di Trapani, Vito Valenti, (unknown), G. de Gregorio, (unknown), (unknown), (unknown), Vincenzo Serretta, Antonio Lo Casto, Giuseppe Ferrera	14
7	Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes 2019 ·Aging Clinical and Experimental Research ·Francesco Cuccia, Alba Fiorentino, Salvatore Corrao, Gianluca Mortellaro, Vito Valenti, (unknown), G. de Gregorio, Vincenzo Serretta, Francesco Verderame, (unknown), Antonio Lo Casto, Giuseppe Ferrera	13
8	Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes 2018 ·Cancer Management and Research ·Francesco Cuccia, Gianluca Mortellaro, Vincenzo Serretta, Vito Valenti, (unknown), (unknown), (unknown), Antonio Lo Casto, Giuseppe Ferrera	18
9	Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy 2018 ·Urology Annals ·Vincenzo Serretta, Alberto Abrate, (unknown), (unknown), (unknown), Fabrizio Di Maida, (unknown), Giuseppe Cicero, Elisabetta Barresi, (unknown)	9
10	Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT) 2016 ·Pathology - Research and Practice ·(unknown), Vincenzo Serretta, Fabrizio Di Maida, Antonino Giulio Giannone, Elisabetta Barresi, Vito Franco, Rodolfo Montironi	2
11	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy 2015 ·Urologic Oncology Seminars and Original Investigations ·Marco Moschini, Andrea Gallina, Massimo Freschi, Stefano Luzzago, Nicola Fossati, Giorgio Gandaglia, Paolo Dell’Oglio, Rocco Damiano, Vincenzo Serretta, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo	14
12	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy 2015 ·Urology Annals ·Vincenzo Serretta, (unknown), (unknown), Vito Franco, Giuseppe Cicero, (unknown)	1
13	A 1‐year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non‐muscle‐invasive bladder cancer 2010 ·British Journal of Urology ·Vincenzo Serretta, Giuseppe Morgia, Vincenzo Altieri, (unknown), Giovanni Maria Ruggiero, Luigi Salzano, Michele Battaglia, Mario Falsaperla, (unknown), (unknown), (unknown), (unknown)	24
14	Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma 2008 ·British Journal of Urology ·Georg C. Hutterer, Pierre I. Karakiewicz, Craig D. Zippe, Gerson Lüdecke, Hans Boman, Marta Sänchez‐Carbayo, Roberto Casella, Christine Mian, Martin Friedrich, Sanaa Eissa, Hideyuki Akaza, Vincenzo Serretta, Hans Hedelin, Rupesh Raina, Naoto Miyanaga, Arthur I. Sagalowsky, Paul Perrotte, Yair Lotan, Michael Marberger, Shahrokh F. Shariat	26
15	Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer 2004 ·British Journal of Cancer ·W. Albrecht, Hendrik Van Poppel, Simon Horenblas, G. Mickisch, Alan Horwich, Vincenzo Serretta, Giovanni Casetta, (unknown), William G. Jones, S. Kálmán, Richard Sylvester	29
16	Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions 2002 ·Urology ·Vincenzo Serretta, Giuseppe Morgia, (unknown), (unknown), (unknown), Domenico Pirritano, D. Melloni, (unknown), Mario Motta, M. Pavone‐Macaluso	174
17	Urinary BTA–Stat, BTA–Trak and NMP22 in Surveillance after TUR of Recurrent Superficial Transitional Cell Carcinoma of the Bladder 2000 ·European Urology ·Vincenzo Serretta, Giorgio Pomara, (unknown), Elisa Espósito	46
18	Endoprosthesis Implantation in the Treatment of Recurrent Urethral Stricture: A Multicenter Study 1999 ·Journal of Endourology ·Giuseppe Morgia, Alberto Saita, (unknown), Claudio Macaluso, Vincenzo Serretta, P. Lanza, (unknown), (unknown), (unknown)	9
19	Intravesical mitoxantrone in superficial bladder tumours (Ta-T1) 1993 ·European Journal of Cancer ·Vincenzo Serretta, (unknown), Carlo Pavone, (unknown)	3
20	Intravesical Therapy of Superficial Bladder T ransitional Cell Carcinoma with Tumor Necrosis Factor-Alpha: Preliminary Report of a Phase I—II Study 1992 ·European Urology ·Vincenzo Serretta, (unknown), (unknown), C.R. Franks, Peter Palmer, (unknown), M. Pavone‐Macaluso	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact